Analytical and clinical validation of Ion Torrent™ Oncomine™ Dx Express Test for identifying PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive advanced breast cancer for treatment with capivasertib.
A rapid genetic test helps identify which breast cancer patients may benefit from a specific targeted therapy.
The study validated a rapid assay for PIK3CA, AKT1, and PTEN alterations linked to capivasertib treatment. The assay showed 89.2% overall agreement with FoundationOne CDx and identified a subgroup with progression-free survival benefit from capivasertib plus fulvestrant.
What the study was
- Study design
- Analytical validation and retrospective clinical validation study
- Population
- 429 residual tumor samples from the phase III CAPItello-291 breast cancer trial
- Sample size
- 429
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Translational oncology
Why it surfaced
The assay has both analytical and trial-linked clinical validation, though its false-negative rate for complex PTEN variants warrants caution
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.